White matter

Eastern NeuroRadiology Society (ENRS 2022) – Braintale Awarded Robert D. Zimmerman Scientific Award for Widening the Usage of Its Digital Platform to Alzheimer’s Disease Patient Identification

Retrieved on: 
Tuesday, August 23, 2022
Biotechnology, Radiology, Health, Neurology, Alzheimer's disease, Brain, Ageing, Solution, Neuroscience, ENRS, Physician, CSO, Disease, MCI, ADNI, Communication, Biomarker, MRI, White matter, Neurological disorder, DTI, Patient, Medical imaging

This is the first evidence of Braintales platform relevance to enable better care for Alzheimers disease patients, reinforced by the Robert D. Zimmerman Scientific Award granted by the scientific committee of ENRS.

Key Points: 
  • This is the first evidence of Braintales platform relevance to enable better care for Alzheimers disease patients, reinforced by the Robert D. Zimmerman Scientific Award granted by the scientific committee of ENRS.
  • Alzheimers disease and related dementia affects more than 36 million people worldwide, with more than 7 million newly diagnosed each year.
  • Braintales digital medical device platform now enables non-invasive ageing patient management in the daily clinical practice.
  • With non-invasive, sensitive and reliable measurements of white matter microstructure alterations, Braintale offers a digital biomarkers platform to support clinical decision-making.

Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis

Retrieved on: 
Thursday, August 11, 2022
Lists of diseases, Medicine, MS, GLOBE, Brain, Incidence, Research, Psychiatry, DNA, Therapy, EAE, KTTA, White matter, Spinal cord, Epstein–Barr virus, Monkeypox virus, Nasdaq, MIAMI, Multiple sclerosis, Immune system, Paralysis, Disease, Vaccine, Nature

MIAMI BEACH, Fla., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of new and effective treatments for psychiatric and neurological disorders, today announced positive results from a preclinical proof of concept study of PAS002, its tolerizing vaccine program in multiple sclerosis (“MS”).  

Key Points: 
  • In this proof of concept study, relapsing paralysis was established in a mouse model of relapsing-remitting experimental autoimmune encephalomyelitis (EAE), the standard animal model of MS.
  • The engineered DNA molecule creates tolerance, working like an inverse vaccine, and was administered intra-muscularly at days 0, 3, 7, 10, and 14.
  • The study was conducted at Hooke Laboratories, an independent full-service Contract Research Organization with deep experience in the EAE animal model of MS.
  • Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea, stated, "Were thrilled with the strong preclinical efficacy data shown in this study.

HIGHLIGHTS FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2022

Retrieved on: 
Wednesday, August 3, 2022
COVID-19, Even and odd functions, Brain, History, Alzheimer's Association, Treatment, Rush Alzheimer's Disease Center, 2009 Davis Cup, HDP, Time, Insulin resistance, Risk, Woman, Hospital, Pathology, SAN, Family, Multimedia, Biology, Association, Safety, Ageing, FDA, Disease, Fats, Research, Network, Friends, Conference, White matter, Pre-eclampsia, Pregnancy, Vascular dementia, Publishing, Hypertension, Patient, Memory, AAIC, Racism, Blood, Therapy, MCI, Cognition, SES, White, Ultra, Smell, Life, Biomarker, Degenerative disease, Exercise, Residential care, Video game, Medical imaging, Toy, Pharmaceutical industry, Birth control, Ridesharing company, Tutoring, ICU, Alzheimer's disease, Latinx, Dementia, Black

SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- New research reported at the Alzheimer's Association International Conference (AAIC) 2022 covered the breadth of Alzheimer's and dementia research, including the basic biology of aging and the brain, risk factors and prevention strategies, and caregiving and living well with the disease.

Key Points: 
  • SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- New research reported at the Alzheimer's Association International Conference (AAIC) 2022 covered the breadth of Alzheimer's and dementia research, including the basic biology of aging and the brain, risk factors and prevention strategies, and caregiving and living well with the disease.
  • The Alzheimer's Association is leading the fight through funding, convening, publishing, partnerships, advocacy and services."
  • The Alzheimer's Association highlighted results from a variety of clinical trials at AAIC 2022.
  • The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias.

HIGHLIGHTS FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2022

Retrieved on: 
Wednesday, August 3, 2022
COVID-19, Even and odd functions, Brain, History, Alzheimer's Association, Treatment, Rush Alzheimer's Disease Center, 2009 Davis Cup, HDP, Time, Insulin resistance, Risk, Woman, Hospital, Pathology, SAN, Family, Biology, Association, Safety, Ageing, FDA, Disease, Fats, Research, Network, Friends, Conference, White matter, Pre-eclampsia, Pregnancy, Vascular dementia, Publishing, Hypertension, Patient, Memory, AAIC, Racism, Blood, Therapy, MCI, Cognition, SES, White, Ultra, Smell, Life, Biomarker, Degenerative disease, Exercise, Residential care, Medical imaging, Toy, Pharmaceutical industry, Birth control, Ridesharing company, Tutoring, ICU, Alzheimer's disease, Latinx, Dementia, Black

SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- New research reported at the Alzheimer's Association International Conference (AAIC) 2022 covered the breadth of Alzheimer's and dementia research, including the basic biology of aging and the brain, risk factors and prevention strategies, and caregiving and living well with the disease.

Key Points: 
  • SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- New research reported at the Alzheimer's Association International Conference (AAIC) 2022 covered the breadth of Alzheimer's and dementia research, including the basic biology of aging and the brain, risk factors and prevention strategies, and caregiving and living well with the disease.
  • The Alzheimer's Association is leading the fight through funding, convening, publishing, partnerships, advocacy and services."
  • The Alzheimer's Association highlighted results from a variety of clinical trials at AAIC 2022.
  • The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias.

Cognito Therapeutics Announces Proprietary Gamma Sensory Stimulation for 6-Months Reduces White Matter Atrophy in Alzheimer’s Disease Patients

Retrieved on: 
Monday, August 1, 2022
Other Health, Software, Research, Pharmaceutical, Data Management, Medical Devices, Technology, Clinical Trials, Science, Biotechnology, Other Science, Health, Pathology, AAIC, Brain, Knowledge, White matter, Dementia, MIT, Twitter, Neurodegeneration, Research, Alzheimer's disease, Optogenetics, Muscle atrophy, Therapy, Multimedia, Conference, HIV disease progression rates, Lists of publishing companies, Clinical trial, AD, Technology, FDA, Atrophy, Patient, Axon, Myelin, Cognito, Medical imaging

Cognito Therapeutics , announced today that its proprietary gamma sensory stimulation at 40Hz over a 6-month period reduced white matter atrophy in the brain for patients with Alzheimers Disease, according to new data presented at the Alzheimers Association International Conference 2022.

Key Points: 
  • Cognito Therapeutics , announced today that its proprietary gamma sensory stimulation at 40Hz over a 6-month period reduced white matter atrophy in the brain for patients with Alzheimers Disease, according to new data presented at the Alzheimers Association International Conference 2022.
  • Although white matter atrophy is observed in normal aging, it is more pronounced in AD patients.
  • White matter degeneration, myelin loss and oligodendrocyte damage in AD patients suggest that white matter can be a mechanistically important target for AD.
  • Our proprietary gamma sensory stimulation therapy for a 6-month period was shown to reduce white matter atrophy, and potentially protect axons, prevent myelin and oligodendrocyte damage in Alzheimers patients, said Brent Vaughan, Chief Executive Officer, Cognito Therapeutics.

Potential Risk for Methadone Treatment in Pregnancy

Retrieved on: 
Wednesday, July 13, 2022
Hospital, Experimental biology, Experimental Biology and Medicine (Society for Experimental Biology and Medicine journal), Methadone, Experimental Biology and Medicine, University of Louisville School of Medicine, Risk, Society, Pregnancy, Brain, Cell death, GLOBE, MTD, Norton Children's Hospital, Arrest, Publishing, Opioid use disorder, White matter, Department, Opioid, University, Medical device, Medical imaging, Medicine, Pediatrics

WASHINGTON, July 13, 2022 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine ( Volume 247, Issue 12, June, 2022 ) identifies a potential risk to using Methadone treatment for opioid dependency in pregnancy.

Key Points: 
  • WASHINGTON, July 13, 2022 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine ( Volume 247, Issue 12, June, 2022 ) identifies a potential risk to using Methadone treatment for opioid dependency in pregnancy.
  • Methadone (MTD) is commonly prescribed to treat opioid dependency in pregnancy.
  • Animal studies suggest a link between in-utero MTD exposure and impaired brain white matter development.
  • This, and prior studies by others, provides support for the idea that methadone treatment for opioid use disorder leads to impaired myelination in the developing brain.

Cognito Therapeutics Announces Data Presentations at the Alzheimer’s Association International Conference 2022

Retrieved on: 
Wednesday, July 13, 2022
Hardware, FDA, Other Health, Technology, Pharmaceutical, Mental Health, Medical Devices, Genetics, Fitness & Nutrition, Clinical Trials, Biotechnology, Science, Software, Other Science, Research, Health, AAIC, Atrophy, Optogenetics, Therapy, Alzheimer's disease, Patient, Neurodegeneration, Lists of publishing companies, Cognito, HIV disease progression rates, MIT, White matter, Dementia, Research, Twitter, FDA, Axon, 2021 Essex County Council election, Pharmaceutical industry, Medical imaging

Cognito Therapeutics , a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, today announced the acceptance of two research abstracts and an oral presentation at the Alzheimers Association International Conference 2022 (AAIC) .

Key Points: 
  • Cognito Therapeutics , a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, today announced the acceptance of two research abstracts and an oral presentation at the Alzheimers Association International Conference 2022 (AAIC) .
  • The largest international meeting dedicated to advancing dementia science, AAIC will be held as an online and in-person event in San Diego, July 31- August 4, 2022.
  • Details of the presentations are as follows:
    To meet with the Cognito team on-site at AAIC, please contact [email protected] .
  • Cognito Therapeutics is a pioneer in disease-modifying therapeutic interventions for neurodegenerative diseases and human cognitive performance.

European Congress of Radiology (ECR 2022) – Braintale Selected for Oral Presentation of Its Digital Biomarkers’ Platform Technical Potential

Retrieved on: 
Tuesday, July 12, 2022
Neurology, Radiology, Biotechnology, Health, Medical Devices, Data Management, Technology, Other Health, Decision-making, Movement, Degenerative disease, ECR, Communication, Ageing, ISO, Acquisition, Medical imaging, Diffusion, MDR, Solution, Neuroscience, Risk, European Medical Writers Association, Patient, European Society of Radiology, Neurodegeneration, Neurological disorder, Brain, Amyotrophic lateral sclerosis, Physician, Artifact, Medical University of Vienna, Health, European Society for Medical Oncology, HIV disease progression rates, White matter, Medical school, Department, Radiology, Hospital, Research, Neurology, Biomarker, DTI, Medical device

Accordingly, Braintale has been developing, since its inception in 2018, non-invasive, accessible, effective and clinically validated measurement and prediction solutions for physicians treating patients suffering from brain diseases.

Key Points: 
  • Accordingly, Braintale has been developing, since its inception in 2018, non-invasive, accessible, effective and clinically validated measurement and prediction solutions for physicians treating patients suffering from brain diseases.
  • The Braintale platform includes AI-processed CE-marked digital solutions, deployed across two modules.
  • I am thrilled to contribute actively and share with my peers the technical benefits of Braintales solution during ECR 2022 meeting.
  • With noninvasive, sensitive and reliable measurements of white matter microstructure alterations, Braintale offers a digital biomarkers platform to support clinical decision-making.

Myrtelle Announces Positive Data for Its investigational Proprietary rAAV-Olig001-ASPA Gene Therapy in Canavan Disease at the National Tay Sachs & Allied Diseases Association Conference

Retrieved on: 
Friday, July 8, 2022
Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Cell, FIH, Inc., Mutation, Science, Intracerebroventricular injection, Boonshoft School of Medicine, Patient, ICV, Magnetic resonance imaging, Brain, Trial of the century, Walking, Metabolism, Disease, Intellectual property, White matter, Irritability, Forward-looking statement, Spasticity, Magnetic resonance, ASPA, Gross, Canavan disease, Kaay Raav Tumhi, MPH, Pfizer, N-Acetylaspartic acid, Clinical trial, Wright, OH, Doctor of Philosophy, Seizure, Pediatrics, CD, Time, Associate, Safety, MRI, VG, Program, NAA, Neurodegeneration, Conference, Pharmaceutical industry, Medical imaging, Canavan, Myrtelle Canavan, Aspartoacylase, MD

In CD, the production of myelin is affected due to a mutation in the Aspartoacylase gene (ASPA) encoding the enzyme Aspartoacylase (ASPA).

Key Points: 
  • In CD, the production of myelin is affected due to a mutation in the Aspartoacylase gene (ASPA) encoding the enzyme Aspartoacylase (ASPA).
  • These improvements suggest the gene therapy and the route of administration are directly targeting the oligodendrocytes, the key cells affected in Canavan disease.
  • Myrtelle Inc. is a gene therapy company focused on developing transformative treatments for neurodegenerative diseases.
  • The company has a proprietary platform, intellectual property, and portfolio of programs and technologies supporting innovative gene therapy approaches for neurodegenerative diseases.

AI In Medical Imaging Market Global Report 2022: Featuring Key Players General Electric, Siemens Healthineers, Koninklijke Philips, IBM & Watson Health

Retrieved on: 
Thursday, July 7, 2022
Efficiency, Diagnosis, Intracranial hemorrhage, Deep learning, Neurology, CMR, Patient, Hospital, Infarction, Intelligence, Industry, White matter, Decision-making, Smartphone, CT, Radiology, Automation, Medicine, Pathology, Stroke, Natural language processing, Physician, MRI, Program, Computer vision, Medical imaging, Medical device

Other advances include smartphone technology integration in AI in medical imaging in which front-line health workers could non-invasively screen for various conditions by leveraging a smartphone.

Key Points: 
  • Other advances include smartphone technology integration in AI in medical imaging in which front-line health workers could non-invasively screen for various conditions by leveraging a smartphone.
  • It gives faster and more accurate results and reduces diagnostic errors at reduced costs compared to traditional medical imaging methods.
  • Thus, radiologists believe that AI in medical imaging may bring an enormous opportunity for its increasing implementation in the upcoming years.
  • Natural language processing, Computer Vision, and Context-Aware Computing technologies are also used to create new analysis methods for medical imaging products.